Development of an adverse outcome pathway for histone deacetylase inhibition leading to axial skeletal defects via histone hyperacetylation: The potential to improve decision making in chemical safety assessments
Computational Toxicology · 2026-12 · 40 · 100463
DOI: 10.1016/j.comtox.2026.100463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Computational Toxicology, 2026-12. Verfasst von Takashi Yamada und 6 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Government of Japan Ministry of Health Labour and Welfare.
Abstract (Originalsprache)
Endpoints of developmental and reproductive toxicity (DART) are of regulatory significance. DART assessments are currently costly, time consuming and require large numbers of animals. Therefore, alternative DART assessment approaches are being developed, and adverse outcome pathways (AOPs) can support these alternative testing paradigms to safety assessment. Here we illustrate the development of a new DART AOP, and its potential application in regulatory decision making. A new DART database, constructed based on studies according to the relevant test guidelines (OECD TG422/TG421) under the Japan Chemical Substances Control Law, was curated and used to identify knowledge gaps in an AOP network. One of the AOPs developed begins with histone deacetylase (HDAC) inhibition as the molecular initiating event, involves key events in three pathways (impairments in gastrulation/osteogenesis/chondrogenesis), and leads to axial skeletal defects as the adverse outcome. The mechanism is well supported by observations from both knockout studies and toxicological studies with structurally diverse HDAC inhibitors. Using valproic acid (VPA) as an example compound, we present a case study which assesses and discusses the benefits of framing assay data around AOPs. The case study explores how AOPs can support the assessor's decision making at multiple stages of a compound's development through contextualising NAMs and facilitating the confident use of these in the DART evaluation strategy.
Förderung
- Government of Japan Ministry of Health Labour and Welfare
Zitieren
APA
Yamada, T., Katsutani, N., Hirose, A., A.Stalford, S., Myden, A., White, E., & Fowkes, A. (2026). Development of an adverse outcome pathway for histone deacetylase inhibition leading to axial skeletal defects via histone hyperacetylation: The potential to improve decision making in chemical safety assessments. Computational Toxicology, 40, 100463. https://doi.org/10.1016/j.comtox.2026.100463
Vancouver
Yamada T, Katsutani N, Hirose A, A.Stalford S, Myden A, White E, et al. Development of an adverse outcome pathway for histone deacetylase inhibition leading to axial skeletal defects via histone hyperacetylation: The potential to improve decision making in chemical safety assessments. Computational Toxicology. 2026;40:100463. doi:10.1016/j.comtox.2026.100463
BibTeX
@article{Yamada2026,
author = {Yamada, Takashi and Katsutani, Naruo and Hirose, Akihiko and A.Stalford, Susanne and Myden, Alun and White, Emma and Fowkes, Adrian},
title = {Development of an adverse outcome pathway for histone deacetylase inhibition leading to axial skeletal defects via histone hyperacetylation: The potential to improve decision making in chemical safety assessments},
journal = {Computational Toxicology},
year = {2026},
volume = {40},
pages = {100463},
doi = {10.1016/j.comtox.2026.100463}
}
EUVIMED